Immunogen (IMGN) Tops Q2 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Total darkness, then sunset as full eclipse wows spectators in Spain
- Burry doubles down on Nebius short after stock surges 34% on earnings
ImmunoGen Reports Recent Progress and Second Quarter 2021 Financial Results
July 30, 2021 6:30 AM EDTCompelling Final Data from FORWARD II Study Combining Mirvetuximab Soravtansine with Avastin® in Recurrent Ovarian Cancer, Regardless of Platinum Status, Presented at ASCO
Top-line Data from Pivotal SORAYA Trial on Track for Q4 Release
Continued Progress in Ongoing MIRASOL, IMGN632, and IMGC936 Studies
Conference Call to be Held at 8:00 a.m. ET Today
WALTHAM, Mass.--(BUSINESS... More
